Effects of the dietary supplements, activated charcoal and copper chlorophyllin, on urinary excretion of trimethylamine in Japanese trimethylaminuria patients
- PMID: 15043988
- DOI: 10.1016/j.lfs.2003.10.022
Effects of the dietary supplements, activated charcoal and copper chlorophyllin, on urinary excretion of trimethylamine in Japanese trimethylaminuria patients
Abstract
Trimethylaminuria (TMAU) is a metabolic disorder characterized by the inability to oxidize and convert dietary-derived trimethylamine (TMA) to trimethylamine N-oxide (TMAO). This disorder has been relatively well-documented in European and North American populations, but no reports have appeared regarding patients in Japan. We identified seven Japanese individuals that showed a low metabolic capacity to convert TMA to its odorless metabolite, TMAO. The metabolic capacity, as defined by the concentration of TMAO excreted in the urine divided by TMA concentration plus TMAO concentration, in these seven individuals ranged from 70 to 90%. In contrast, there were no healthy controls examined with less than 95% of the metabolic capacity to convert TMA to TMAO. The intake of dietary charcoal (total 1.5 g charcoal per day for 10 days) reduced the urinary free TMA concentration and increased the concentration of TMAO to normal values during charcoal administration. Copper chlorophyllin (total 180 mg per day for 3 weeks) was also effective at reducing free urinary TMA concentration and increasing TMAO to those of concentrations present in normal individuals. In the TMAU subjects examined, the effects of copper chlorophyllin appeared to last longer (i.e., several weeks) than those observed for activated charcoal. The results suggest that the daily intake of charcoal and/or copper chlorophyllin may be of significant use in improving the quality of life of individuals suffering from TMAU.
Similar articles
-
Diagnosis of suspected trimethylaminuria by NMR spectroscopy.Clin Chim Acta. 2005 Jan;351(1-2):149-54. doi: 10.1016/j.cccn.2004.09.006. Clin Chim Acta. 2005. PMID: 15563884
-
Genetic analysis of impaired trimethylamine metabolism using whole exome sequencing.BMC Med Genet. 2017 Feb 15;18(1):11. doi: 10.1186/s12881-017-0369-8. BMC Med Genet. 2017. PMID: 28196478 Free PMC article.
-
Trimethylaminuria: the detection of carriers using a trimethylamine load test.J Inherit Metab Dis. 1989;12(1):80-5. doi: 10.1007/BF01805534. J Inherit Metab Dis. 1989. PMID: 2501587
-
Treatments of trimethylaminuria: where we are and where we might be heading.Drug Discov Today. 2020 Sep;25(9):1710-1717. doi: 10.1016/j.drudis.2020.06.026. Epub 2020 Jun 29. Drug Discov Today. 2020. PMID: 32615074 Review.
-
Trimethylamine and Trimethylamine N-Oxide, a Flavin-Containing Monooxygenase 3 (FMO3)-Mediated Host-Microbiome Metabolic Axis Implicated in Health and Disease.Drug Metab Dispos. 2016 Nov;44(11):1839-1850. doi: 10.1124/dmd.116.070615. Epub 2016 May 17. Drug Metab Dispos. 2016. PMID: 27190056 Free PMC article. Review.
Cited by
-
A Macroporous Magnesium Oxide-Templated Carbon Adsorbs Shiga Toxins and Type III Secretory Proteins in Enterohemorrhagic Escherichia coli, Which Attenuates Virulence.Front Microbiol. 2022 May 6;13:883689. doi: 10.3389/fmicb.2022.883689. eCollection 2022. Front Microbiol. 2022. PMID: 35602086 Free PMC article.
-
Adaptive Modelling of Mutated FMO3 Enzyme Could Unveil Unexplored Scenarios Linking Variant Haplotypes to TMAU Phenotypes.Molecules. 2021 Nov 22;26(22):7045. doi: 10.3390/molecules26227045. Molecules. 2021. PMID: 34834137 Free PMC article.
-
Le Carbone prevents liver damage in non-alcoholic steatohepatitis-hepatocellular carcinoma mouse model via AMPKα-SIRT1 signaling pathway activation.Heliyon. 2021 Jan 5;7(1):e05888. doi: 10.1016/j.heliyon.2020.e05888. eCollection 2021 Jan. Heliyon. 2021. PMID: 33490669 Free PMC article.
-
Impact of trimethylaminuria on daily psychosocial functioning.JIMD Rep. 2020 Oct 6;57(1):67-75. doi: 10.1002/jmd2.12170. eCollection 2021 Jan. JIMD Rep. 2020. PMID: 33473342 Free PMC article.
-
Faecal microbiota transplantation in patients with Clostridium difficile and significant comorbidities as well as in patients with new indications: A case series.World J Gastroenterol. 2017 Oct 21;23(39):7174-7184. doi: 10.3748/wjg.v23.i39.7174. World J Gastroenterol. 2017. PMID: 29093626 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
